Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291076 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
A Phase 1 study of Hepatocellular Carcinoma (HCC), sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT07291076: Recruiting Phase 1 study of Hepatocellular Carcinoma (HCC), sponsored by Bristol-Myers Squibb.
NCT07291076 is a Phase 1 study of Hepatocellular Carcinoma (HCC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 129 participants, below the 343-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07291076, a Phase 1 study of Hepatocellular Carcinoma (HCC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Primary Outcome
Phase 1
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Ipilimumab
- DRUG Pumitamig
Study Locations (20)
Tennessee
- Local Institution - 0022 - Nashville
- Local Institution - 0102 - Nashville
New South Wales
- Local Institution - 0024 - Camperdown
- Local Institution - 0033 - Westmead
Santiago Metropolitan
- Local Institution - 0064 - Santiago
- Local Institution - 0106 - Santiago Region Metropolitana
California
- Local Institution - 0070 - Los Angeles
Illinois
- Local Institution - 0107 - Chicago
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
New York
- Local Institution - 0100 - Great Neck
Oregon
- Local Institution - 0080 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2031-10-14 |
| Phase | Phase 1 |
What NCT07291076 shows while recruiting
NCT07291076 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 343-participant average among 15 other Hepatocellular Carcinoma (HCC) trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Hepatocellular Carcinoma (HCC) appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07291076 names 20 study sites across 17 states, led by Tennessee, New South Wales, Santiago Metropolitan.
Frequently Asked Questions
What is clinical trial NCT07291076 about?
NCT07291076 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)". The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
What is the current status of trial NCT07291076?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2026-03-31. Estimated completion is 2031-10-14.
What conditions does trial NCT07291076 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma (HCC).
What interventions are being tested in trial NCT07291076?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Ipilimumab (DRUG), Pumitamig (DRUG).
Who is sponsoring clinical trial NCT07291076?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07291076 being conducted?
This trial has 20 study locations across California, Illinois, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma (HCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07291076's enrollment target sits among peer trials
129 10th of 15 higher than 6 of 15 other Hepatocellular Carcinoma (HCC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma (HCC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 1
-
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI